
    
      An observational, multi-center, prospective cohort study to assess the effectiveness and
      safety of generic Imatinib (Carcemia®) in patients with Ph+ CML who are newly diagnosed or
      patients who will be switched from the reference product (Glivec® ) to Carcemia® where
      treatment will be prescribed by the investigator in accordance with clinical practice where
      no visits or intervention(s) additional to the daily practice will be performed.

      Eligible Ph+ CML patients in both cohorts will be followed up for a total of 18 months.
    
  